ATI-2341 is a potent and functionally selective allosteric agonist of C-X-C chemokine receptor type 4 (CXCR4), which functions as a biased ligand, favoring Gαi activation over Gα13. ATI-2341 activates the inhibitory heterotrimeric G protein (Gi) to promote inhibition of cAMP production and induce calcium mobilization. ATI-2341 is a potent and efficacious mobilizer of bone marrow polymorphonuclear neutrophils (PMNs) and hematopoietic stem and progenitor cells (HSPCs).
CAT No: R1220
CAS No:1337878-62-2
Synonyms/Alias:ATI-2341;1337878-62-2;palmitoyl-Met-Gly-Tyr-Gln-Lys-Lys-Leu-Arg-Ser-Met-Thr-Asp-Lys-Tyr-Arg-Leu-OH;HY-P0172;MDC87862;s8309;AKOS027470291;CCG-270699;CS-0020801;
ATI-2341 is a synthetic peptide compound designed as a selective agonist for the CXC chemokine receptor 4 (CXCR4). As a structurally engineered peptide, it mimics endogenous chemokines in its ability to modulate receptor-mediated signaling pathways. Its high affinity and specificity for CXCR4 make it a valuable molecular tool for dissecting chemokine-receptor interactions and understanding the roles of CXCR4 in diverse physiological and pathological processes. The compound's unique peptide sequence allows researchers to probe receptor activation, downstream signaling cascades, and cellular responses with precision, supporting advanced studies in immunology, oncology, and cell signaling.
Receptor Pharmacology: ATI-2341 is widely utilized in receptor pharmacology research to characterize the ligand-binding properties and activation mechanisms of CXCR4. By serving as a potent agonist, this peptide enables detailed mapping of receptor-ligand interactions, facilitating the identification of critical amino acid residues involved in CXCR4 activation. Its application in binding assays and functional studies supports the elucidation of receptor conformational changes, signaling bias, and the development of structure-activity relationships for novel chemokine analogs.
Signal Transduction Studies: In cellular signaling research, the compound provides a robust means to initiate and monitor CXCR4-mediated pathways. Investigators employ ATI-2341 to stimulate G protein-coupled receptor (GPCR) cascades, allowing for the analysis of downstream effectors such as calcium flux, MAPK activation, and chemotactic responses. Its use in these studies aids in distinguishing CXCR4-specific signaling events from those mediated by other chemokine receptors, thereby clarifying the unique contributions of CXCR4 to cellular physiology.
Immune Cell Migration Assays: The peptide is instrumental in studies of immune cell trafficking and chemotaxis. By activating CXCR4 on lymphocytes, monocytes, or other relevant cell types, researchers can quantitatively assess cell migration in response to chemokine gradients. This application is particularly valuable for modeling leukocyte homing, tissue infiltration, and the regulation of immune surveillance, providing insights into the dynamic interplay between chemokine signals and immune cell behavior.
Oncology and Tumor Microenvironment Research: ATI-2341 supports investigation into the role of CXCR4 in cancer biology, including tumor cell migration, invasion, and metastasis. Its ability to selectively activate CXCR4 enables the study of how chemokine signaling influences tumor-stromal interactions, angiogenesis, and the metastatic cascade. By employing this peptide in in vitro and ex vivo systems, researchers can dissect the contribution of chemokine-driven pathways to cancer progression and identify potential molecular targets for further exploration.
Peptide-Based Drug Discovery: As a synthetic chemokine analog, ATI-2341 serves as a reference compound in the development and screening of novel CXCR4 modulators. Its well-characterized activity profile makes it suitable for use in high-throughput screening assays, competitive binding studies, and functional validation of new peptide or small molecule candidates. The compound's application in these contexts accelerates the identification of next-generation chemokine receptor ligands, supporting both basic research and preclinical discovery efforts.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More